Dialysis culture for determination of MIC and MBC of benzylpenicillin against Borrelia burgdorferi

APMIS

Volumn 107, Issue 4, 1999, Pages 380-382

  Stiernstedt, Susanne Hammers ^a   Tadesse, Tekleweini ^b   Wretlind, Bengt ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Benzylpenicillin; Borrelia burgdorferi; Dialysis culture; MIC MBC

Indexed keywords

PENICILLIN G;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIOSTASIS; BACTERIUM CULTURE; BORRELIA BURGDORFERI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0032917558     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01568.x     Document Type: Article

References (19)

1. 1. Berger BW, Kaplan MH, Rothenberg IR, Barbour AG. Isolation and characterization of the Lyme disease spirochete from the skin of patients with erythma chronicum migrans. J Am Acad Dermatol 1985;13:444-9.
2. 2. Berger BW, Johnson RC. Clinical and microbiologic findings in six patients with erythema migrans of Lyme disease. J Am Acad Dermatol 1989;21:1188-91.
3. 3. Hansen K, Hovmark A, Lebech A-M, Lebech K, Olsson I, Halkier-Sørensen L, et al. Roxithromyein in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans. Acta Derm Venereol 1992;72:297-300.
4. 4. Johnson RC, Kodner C, Russell M. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob Agents Chemother 1987;31: 164-7.
5. 5. Johnson RC, Kodner CB, Jurkovich PJ, Collins JJ. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxim and other antimicrobial agents. Antimicrob Agents Chemother 1990;34: 2133-6.
6. 6. Johnson RC. Isolation tehcniques for spirochetes and their sensitivity to antibiotics in vitro and in vivo. Rev Infect Dis Suppl 6 1989;11:1505-10.
7. 7. Johnson SE, Klein GC, Schmid GP, Feeley JC. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents. Yale J Biol Med 1984;57:549-53.
8. 8. Luft BJ, Volkman DJ, Halperin JJ, Dattwyler RJ. New chemotherapeutic approaches in the treatment of Lyme borreliosis. Ann NY Acad Sci 1988;539:352-61.
9. 9. Preac-Mursic V, Wilske B, Schiertz G. European Borrelia burgdorferi isolated from humans and ticks. Culture conditions and antibiotic susceptibility. Zbl Bakt Hyg 1986;A 263:112-8.
10. 10. Preac-Mursic V, Wilske B, Schierz G, Holmburger M, Süss E. In vitro and in vivo susceptibility of Borrelia burgdorferi. Eur J Clin Microbiol 1987;6:424-6.
11. 11. Philipson A. Antibiotic treatment in Lyme borreliosis. Scand J Infect Dis 1991; Suppl 77: 145-50.
12. 12. Dever LL, Jorgensen JH, Barbour AG. In vitro susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol 1992;30:2692-7.
13. 13. Stiernstedt SH, Wretlind B. Dialysis culture enables more accurate determination of MIC of benzylpenicillin for Borrelia burgdorferi than does conventional procedure. Antimicrob Agents Chemother 1996;40:2882-3.
14. 14. Baradaran-Dilmaghani R, Stanek G. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection 1996;24:60-3.
15. 15. Steere AC, Grodzicki RL, Kornblatt AN, Craft JE, Barbour AG, Burgdorfer W, et al. The spirochetal etiology of Lyme disease. N Engl J Med 1983;308:733-40.
16. 16. Stiernstedt G. Tick-borne Borrelia infection in Sweden. Scand J Infect Dis 1985; Suppl 45:1-70.
17. 17. Hansen K, Lebech AM, Lebech K. Is Borrelia burgdorferi a penicillin-sensitive organism? An in vitro and in vivo animal study. Fifth International Conference on Lyme borreliosis, Arlington, VA 1992, abstract 13.
18. 18. Sabath LD, Wheeler M, Laverdière M, Blazevic D, Wilkinson BJ. A new type of penicillin resistance of Staphylococcus aureus. Lancet 1997;i: 443 -7.
19. 19. Fluckiger U, Moreillon P, Blaser J, Bickle M, Glauser MP, Francioli P. Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats. Antimicrob Agents Chemother 1994;38:2846-9.